Evidence map›Paper›PMID 40536683›Full record

ArticleBasic research in cardiology2025

The innate immune receptor NLRX1 is a novel required modulator for mPTP opening: implications for cardioprotection.

Y Xiao, X Hu, C F Rudolphi, E E Nollet, R Nederlof, Q Wang, D Bakker, Panagiota Efstathia Nikolaou, J C Knol, R R Goeij-de Haas and 17 more

Abstract read
In one paragraph

Article in Basic research in cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Phenotypic CRISPR screens identify NLRX1 as an essential activator of the human mitochondrial permeability transition.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Y Xiao *Laboratory of Experimental Intensive Care and Anesthesiology, Department of Anesthesiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
X Hu *Laboratory of Experimental Intensive Care and Anesthesiology, Department of Anesthesiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
C F RudolphiLaboratory of Experimental Intensive Care and Anesthesiology, Department of Anesthesiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
E E NolletAmsterdam Cardiovascular Sciences, Atherosclerosis & Ischemic Syndromes, Heart Failure & Arrhythmias, Amsterdam, The Netherlands.
R NederlofInstitut Für Herz- Und Kreislaufphysiologie, Medizinische Fakultät Und Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
Q WangLaboratory of Experimental Intensive Care and Anesthesiology, Department of Anesthesiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
D BakkerLaboratory of Experimental Intensive Care and Anesthesiology, Department of Anesthesiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Panagiota Efstathia NikolaouLaboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
J C KnolProteomics Core Resource, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands.
R R Goeij-de HaasProteomics Core Resource, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands.
A A HennemanProteomics Core Resource, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands.
T V PhamProteomics Core Resource, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands.
C R JimenezProteomics Core Resource, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands.
A E GrootemaatElectron Microscopy Centre Amsterdam, Medical Biology, Amsterdam University Medical Centre (UMC), Amsterdam, The Netherlands.
N N van der WelElectron Microscopy Centre Amsterdam, Medical Biology, Amsterdam University Medical Centre (UMC), Amsterdam, The Netherlands.
S E GirardinDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
N KaludercicNeuroscience Institute, National Research Council of Italy, Via U. Bassi 58/B, 35121, Padua, Italy.
J van der VeldenAmsterdam Cardiovascular Sciences, Atherosclerosis & Ischemic Syndromes, Heart Failure & Arrhythmias, Amsterdam, The Netherlands.
Z OnódiHCEMM-SE Cardiometabolic Immunology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
P LeszekDepartment of Heart Failure and Transplantology, Cardinal Stefan Wyszyński National Institute of Cardiology, 04-628, Warsaw, Poland.
Z V VargaHCEMM-SE Cardiometabolic Immunology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
P FerdinandyHCEMM-SE Cardiometabolic Immunology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
B PreckelLaboratory of Experimental Intensive Care and Anesthesiology, Department of Anesthesiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
N C WeberLaboratory of Experimental Intensive Care and Anesthesiology, Department of Anesthesiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
M W HollmannLaboratory of Experimental Intensive Care and Anesthesiology, Department of Anesthesiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
F Di LisaNeuroscience Institute, National Research Council of Italy, Via U. Bassi 58/B, 35121, Padua, Italy.
C J ZuurbierLaboratory of Experimental Intensive Care and Anesthesiology, Department of Anesthesiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. c.j.zuurbier@amsterdamumc.nl.ORCID 0000-0001-8361-2448

Funding

Boehringer Ingelheim Stiftung research grantDutch Cardiovascular Alliance 2021EFSD 2018Fondation Leducq 16cvd04Fondation Leducq 20CVD01Horizon 2020 Framework Programme EU-Cardioprotection CA16225HORIZON EUROPE European Innovation Council 739593HORIZON EUROPE Framework Programme EU-Cardioprotection CA16225National Natural Science Foundation of China 82400401New National ExcellenceProgrm of the Ministry of Human Capacities unkp-22-4-ii-se-3NWO 91818602NWO-ZonMW 91818602ZON-MW 2021/38315/ZONMW
6 · The paper itself

Abstract

NLRX1 is the only NOD-like innate immune receptor that localises to mitochondria. We previously demonstrated that NLRX1 deletion increased infarct size in isolated mouse hearts subjected to ischemia-reperfusion injury (IRI); however, underlying mechanisms are yet to be identified. Given the crucial role played by mitochondria in cardiac IRI, we here hypothesise that NLRX1 affects key mechanisms of cardiac IRI. Cardiac IRI was evaluated in isolated C57BL/6J (WT) and NLRX1 knock out (KO) mouse hearts. The following known modulators of IRI were explored in isolated hearts, isolated mitochondria; or permeabilised cardiac fibres: 1) mTOR/RISK/autophagy regulation, 2) AMPK and mitochondrial energy production, and 3) mitochondrial permeability transition pore (mPTP) opening. NLRX1 deletion increased IRI, and cardiac NLRX1 was decreased after IRI in mouse and pig hearts. NLRX1 ablation caused decreased mTOR and RISK pathway (Akt, ERK, and S6K) activation following IR, without affecting autophagy/inflammation/oxidative stress markers. The RISK activator Urocortin dissipated NLRX1 effects on mTOR, RISK pathway and IRI, indicating that increased cardiac IRI with NLRX1 deletion is, at least partly, due to impaired RISK activation. The energy sensor AMPK was activated in NLRX1 KO hearts, possibly due to slowed mitochondrial respiratory responses (impaired mitochondrial permeability) towards palmitoylcarnitine in permeabilised cardiac fibres. NLRX1 deletion completely abolished calcium-induced mPTP opening, and cyclosporine A (CsA) effects on mPTP, both before and after IR, and was associated with increased mitochondrial calcium content after IR. Mitochondrial sub-fractionation studies localised NLRX1 to the inner mitochondrial membrane. NLRX1 deletion associated with decreased phosphorylation of mitochondrial Got2, Cx43, Myl2, Ndufb7 and MICOS10. The mPTP inhibitor CsA abolished IRI differences between KO and WT hearts, suggesting that the permanent closure of mPTP due to NLRX1 deletion contributed to the increased IR sensitivity of NLRX1 KO hearts. This is the first demonstration that the mitochondrial NLRX1 is a novel factor required for mPTP opening and contributes to cardioprotection against acute IRI through RISK pathway activation and prevention of permanent mPTP closure.

Indexed as

Immunity, InnateMitochondria, HeartMitochondrial Membrane Transport ProteinsMitochondrial ProteinsMyocardial InfarctionMyocardial Reperfusion InjuryAnimalsDisease Models, AnimalMaleMiceMice, Inbred C57BLMice, KnockoutMitochondrial Permeability Transition PoreSignal TransductionTOR Serine-Threonine KinasesMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition PoreMitochondrial ProteinsNLRX1 protein, mouseTOR Serine-Threonine KinasesAMPKI/R injuryMitochondriaMitochondrial transition pore openingNLRX1RISK pathway

Identifiers

PMID40536683
PMCPMC12325489

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.